
Lopixibat chloride
CAS No. 228113-66-4
Lopixibat chloride( LUM-001 | HP-625 )
Catalog No. M13626 CAS No. 228113-66-4
Lopixibat chloride (LUM-001, HP-625) is a potent, selectiove, oral inhibitor of sodium bile acid cotransporter and Ileal bile acid transporter (IBAT).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 709 | Get Quote |
![]() ![]() |
10MG | 972 | Get Quote |
![]() ![]() |
25MG | 1467 | Get Quote |
![]() ![]() |
50MG | 1962 | Get Quote |
![]() ![]() |
100MG | 2673 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameLopixibat chloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionLopixibat chloride (LUM-001, HP-625) is a potent, selectiove, oral inhibitor of sodium bile acid cotransporter and Ileal bile acid transporter (IBAT).
-
DescriptionLopixibat chloride (LUM-001, HP-625) is a potent, selectiove, oral inhibitor of sodium bile acid cotransporter and Ileal bile acid transporter (IBAT).Hypercholesterolemia Phase 2 Clinical.
-
In Vitro——
-
In VivoMaralixibat chloride reduces elevations in sBA levels, improves liver function, and reduces liver tissue damage, in a rat partial bile duct ligation model of cholestasis.
-
SynonymsLUM-001 | HP-625
-
PathwayMembrane Transporter/Ion Channel
-
TargetASBT Transporter
-
RecptorASBT Transporter
-
Research AreaCardiovascular Disease
-
IndicationHypercholesterolemia
Chemical Information
-
CAS Number228113-66-4
-
Formula Weight710.415
-
Molecular FormulaC40H56ClN3O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (70.38 mM)
-
SMILES——
-
Chemical Name1-(4-((4-((4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium chloride
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
Volixibat
A highly potent and selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) in development for the treatment of nonalcoholic steatohepatitis (NASH).
-
A4250
A4250 (A-4250, Odevixibat) is a small molecule ileal bile acid transporter (IBAT) inhibitor for the treatment of cholestatic liver diseases including progressive familial intrahepatic cholestasis and NASH.
-
Linerixibat
A highly potent, selective, ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor with IC50 of 2.1/1.9 nM for mouse/rat ASBT, respectively.